Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Breast Cancer

  Free Subscription


29.01.2018

1 AJR Am J Roentgenol
1 Am J Clin Oncol
1 Am J Surg
2 Ann Oncol
1 Ann Surg Oncol
4 BMC Cancer
4 Br J Cancer
4 Breast Cancer
4 Breast Cancer Res
7 Breast Cancer Res Treat
2 Breast J
1 Cancer Epidemiol Biomarkers Prev
1 Cancer Lett
6 Cancer Res
1 Clin Breast Cancer
1 Clin Cancer Res
1 Exp Cell Res
1 Int J Cancer
2 Int J Radiat Oncol Biol Phys
5 J Clin Oncol
1 J Natl Cancer Inst
1 J Surg Oncol
1 Nat Rev Clin Oncol
1 NPJ Breast Cancer
5 Oncogene
2 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. JAVITT MC
    Section Editor's Notebook: Breast Cancer Screening-What Now, and What Next?
    AJR Am J Roentgenol. 2018;210:239-240.
    PubMed     Text format    


    Am J Clin Oncol

  2. JEROME-D'EMILIA B, Kushary D, Burrell SA, Suplee PD, et al
    Breast Cancer Stage at Diagnosis in a New Jersey Cancer Education and Early Detection Site.
    Am J Clin Oncol. 2018 Jan 22. doi: 10.1097/COC.0000000000000425.
    PubMed     Text format     Abstract available


    Am J Surg

  3. SUTTON T, Reilly P, Johnson N, Garreau JR, et al
    Breast cancer in women under 50: Most are not high risk.
    Am J Surg. 2018 Jan 11. pii: S0002-9610(17)31563.
    PubMed     Text format     Abstract available


    Ann Oncol

  4. BARECHE Y, Venet D, Ignatiadis M, Aftimos P, et al
    Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
    Ann Oncol. 2018 Jan 22. pii: 4819112. doi: 10.1093.
    PubMed     Text format     Abstract available

  5. HARTMAIER RJ, Trabucco SE, Priedigkeit N, Chung JH, et al
    Recurrent hyperactive ESR1 fusion proteins in endocrine therapy resistant breast cancer.
    Ann Oncol. 2018 Jan 19. pii: 4817340. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  6. KANTOR O, Sipsy LM, Yao K, James TA, et al
    A Predictive Model for Axillary Node Pathologic Complete Response after Neoadjuvant Chemotherapy for Breast Cancer.
    Ann Surg Oncol. 2018 Jan 24. pii: 10.1245/s10434-018-6345.
    PubMed     Text format     Abstract available


    BMC Cancer

  7. PARK VY, Kim EK, Kim MJ, Moon HJ, et al
    Breast magnetic resonance imaging for surveillance of women with a personal history of breast cancer: outcomes stratified by interval between definitive surgery and surveillance MR imaging.
    BMC Cancer. 2018;18:91.
    PubMed     Text format     Abstract available

  8. DE LIGT KM, Witteveen A, Siesling S, Steuten LMG, et al
    Shifting breast cancer surveillance from current hospital setting to a community based setting: a cost-effectiveness study.
    BMC Cancer. 2018;18:96.
    PubMed     Text format     Abstract available

  9. HAQUE I, Ghosh A, Acup S, Banerjee S, et al
    Leptin-induced ER-alpha-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway.
    BMC Cancer. 2018;18:99.
    PubMed     Text format     Abstract available

  10. RICCIARDI GRR, Russo A, Franchina T, Schifano S, et al
    Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.
    BMC Cancer. 2018;18:97.
    PubMed     Text format     Abstract available


    Br J Cancer

  11. JOHNS LE, Jones ME, Schoemaker MJ, McFadden E, et al
    Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study.
    Br J Cancer. 2018 Jan 23. pii: bjc2017359. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available

  12. PLYM A, Bower H, Fredriksson I, Holmberg L, et al
    Loss in working years after a breast cancer diagnosis.
    Br J Cancer. 2018 Jan 23. pii: bjc2017456. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available

  13. FOUKAKIS T, Lovrot J, Matikas A, Zerdes I, et al
    Immune gene expression and response to chemotherapy in advanced breast cancer.
    Br J Cancer. 2018 Jan 25. pii: bjc2017446. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available

  14. GOEDERT JJ, Hua X, Bielecka A, Okayasu I, et al
    Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota.
    Br J Cancer. 2018 Jan 23. pii: bjc2017435. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Breast Cancer

  15. KHAN RT, Siddique A, Shahid N, Khokher S, et al
    Breast cancer risk associated with genes encoding DNA repair MRN complex: a study from Punjab, Pakistan.
    Breast Cancer. 2018 Jan 24. pii: 10.1007/s12282-018-0837.
    PubMed     Text format     Abstract available

  16. NGUYEN-THU H, Hanaoka H, Nakajima T, Yamaguchi A, et al
    Early prediction of triple negative breast cancer response to cisplatin treatment using diffusion-weighted MRI and (18)F-FDG-PET.
    Breast Cancer. 2018 Jan 22. pii: 10.1007/s12282-018-0834.
    PubMed     Text format     Abstract available

  17. OZAKI Y, Tanabe Y, Tamura N, Ogura T, et al
    Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
    Breast Cancer. 2018 Jan 22. pii: 10.1007/s12282-018-0836.
    PubMed     Text format     Abstract available

  18. YANG ZJ, Yu Y, Chi JR, Guan M, et al
    The combined pN stage and breast cancer subtypes in breast cancer: a better discriminator of outcome can be used to refine the 8th AJCC staging manual.
    Breast Cancer. 2018 Jan 20. pii: 10.1007/s12282-018-0833.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  19. BUSBY J, Mills K, Zhang SD, Liberante FG, et al
    Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study.
    Breast Cancer Res. 2018;20:4.
    PubMed     Text format     Abstract available

  20. MA H, Ursin G, Xu X, Lee E, et al
    Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis.
    Breast Cancer Res. 2018;20:5.
    PubMed     Text format     Abstract available

  21. YANG H, He W, Eriksson M, Li J, et al
    Inherited factors contribute to an inverse association between preeclampsia and breast cancer.
    Breast Cancer Res. 2018;20:6.
    PubMed     Text format     Abstract available

  22. WEBER-LASSALLE N, Hauke J, Ramser J, Richters L, et al
    BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
    Breast Cancer Res. 2018;20:7.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  23. NAROD SA, Sopik V
    Is invasion a necessary step for metastases in breast cancer?
    Breast Cancer Res Treat. 2018 Jan 20. pii: 10.1007/s10549-017-4644.
    PubMed     Text format     Abstract available

  24. JONES T, Duquette D, Underhill M, Ming C, et al
    Surveillance for cancer recurrence in long-term young breast cancer survivors randomly selected from a statewide cancer registry.
    Breast Cancer Res Treat. 2018 Jan 20. pii: 10.1007/s10549-018-4674.
    PubMed     Text format     Abstract available

  25. ABRAHAM J, Caldera H, Coleman R, Elias A, et al
    Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG).
    Breast Cancer Res Treat. 2018 Jan 19. pii: 10.1007/s10549-018-4662.
    PubMed     Text format     Abstract available

  26. FAN Z, Ouyang T, Li J, Wang T, et al
    Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients.
    Breast Cancer Res Treat. 2018 Jan 22. pii: 10.1007/s10549-018-4673.
    PubMed     Text format     Abstract available

  27. POURCELOT C, Orillard E, Nallet G, Dirand C, et al
    Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence.
    Breast Cancer Res Treat. 2018 Jan 23. pii: 10.1007/s10549-018-4676.
    PubMed     Text format     Abstract available

  28. GOYAL NG, Levine BJ, Van Zee KJ, Naftalis E, et al
    Trajectories of quality of life following breast cancer diagnosis.
    Breast Cancer Res Treat. 2018 Jan 24. pii: 10.1007/s10549-018-4677.
    PubMed     Text format     Abstract available

  29. ZHANG L, Yu Q, Wu XC, Hsieh MC, et al
    Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative.
    Breast Cancer Res Treat. 2018 Jan 24. pii: 10.1007/s10549-017-4646.
    PubMed     Text format     Abstract available


    Breast J

  30. WEINER A, D'Andrea GM
    Hidden estrogen production from ovarian remnants leading to progression of disease in metastatic breast cancer.
    Breast J. 2018 Jan 22. doi: 10.1111/tbj.12972.
    PubMed     Text format     Abstract available

  31. BARROU J, Tallet A, Cohen M, Bannier M, et al
    Contribution of intraoperative radiotherapy (IORT) for therapeutic de-escalation in early breast cancer: Report of a single institution's experience.
    Breast J. 2018 Jan 22. doi: 10.1111/tbj.12993.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  32. ZHENG J, Tabung FK, Zhang J, Liese AD, et al
    Association between post-cancer diagnosis dietary inflammatory potential and mortality among invasive breast cancer survivors in the Women's Health Initiative.
    Cancer Epidemiol Biomarkers Prev. 2018 Jan 22. pii: 1055-9965.EPI-17-0569.
    PubMed     Text format     Abstract available


    Cancer Lett

  33. JIN Y, Hu W, Liu T, Rana U, et al
    Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel.
    Cancer Lett. 2018 Jan 23. pii: S0304-3835(18)30087.
    PubMed     Text format     Abstract available


    Cancer Res

  34. LUDWIK KA, McDonald OG, Brenin DR, Lannigan DA, et al
    ERalpha-mediated nuclear sequestration of RSK2 is required for ER+ breast cancer tumorigenesis.
    Cancer Res. 2018 Jan 19. pii: 0008-5472.CAN-17-2063.
    PubMed     Text format     Abstract available

  35. JIAO X, Velasco-Velazquez MA, Wang M, Li Z, et al
    CCR5 governs DNA damage and breast cancer stem cell expansion.
    Cancer Res. 2018 Jan 22. pii: 0008-5472.CAN-17-0915.
    PubMed     Text format     Abstract available

  36. WERFEL TA, Wang S, Jackson MA, Kavanaugh TE, et al
    Selective mTORC2 inhibitor therapeutically blocks breast cancer cell growth and survival.
    Cancer Res. 2018 Jan 22. pii: 0008-5472.CAN-17-2388.
    PubMed     Text format     Abstract available

  37. EVANS MK, Brown MC, Geradts J, Bao X, et al
    XIAP regulation by MNK links MAPK and NFkappaB signaling to determine an aggressive breast cancer phenotype.
    Cancer Res. 2018 Jan 19. pii: 0008-5472.CAN-17-1667.
    PubMed     Text format     Abstract available

  38. ZHANG Y, Manjunath M, Zhang S, Chasman D, et al
    Integrative genomic analysis predicts causative cis-regulatory mechanisms of the breast cancer-associated genetic variant rs4415084.
    Cancer Res. 2018 Jan 19. pii: 0008-5472.CAN-17-3486.
    PubMed     Text format     Abstract available

  39. NAGAHASHI M, Yamada A, Katsuta E, Aoyagi T, et al
    Targeting the SphK1/S1P/S1PR1 axis that links obesity, chronic inflammation and breast cancer metastasis.
    Cancer Res. 2018 Jan 19. pii: 0008-5472.CAN-17-1423.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  40. BHAVE MA, Speth KA, Kidwell KM, Lyden A, et al
    Effect of Aromatase Inhibitor Therapy on Sleep and Activity Patterns in Early-stage Breast Cancer.
    Clin Breast Cancer. 2017 Dec 27. pii: S1526-8209(17)30624.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  41. PIGGOTT L, da Silva AM, Robinson T, Santiago-Gomez A, et al
    Acquired resistance of ER- positive breast cancer to endocrine treatment confers an adaptive sensitivity to TRAIL through post-translational downregulation of c-FLIP.
    Clin Cancer Res. 2018 Jan 23. pii: 1078-0432.CCR-17-1381.
    PubMed     Text format     Abstract available


    Exp Cell Res

  42. MOREIRA MP, da Conceicao Braga L, Cassali GD, Silva LM, et al
    STAT3 as a promising chemoresistance biomarker associated with the CD44(+/high)/CD24(-/low)/ALDH(+) BCSCs-like subset of the triple-negative breast cancer (TNBC) cell line.
    Exp Cell Res. 2018 Jan 15. pii: S0014-4827(18)30027.
    PubMed     Text format     Abstract available


    Int J Cancer

  43. RIAHI A, Radmanesh H, Schurmann P, Bogdanova N, et al
    Exome sequencing and case-control analyses identify RCC1 as a candidate breast cancer susceptibility gene.
    Int J Cancer. 2018 Jan 24. doi: 10.1002/ijc.31273.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  44. WRIGHT J, Blitzblau R
    Cardiac Morbidity and Radiation Therapy for Breast Cancer.
    Int J Radiat Oncol Biol Phys. 2018;100:283-286.
    PubMed     Text format    


  45. Erratum to: Wang SY, Kelly G, Gross C, et al. Information needs of older women with early-stage breast cancer when making radiation therapy decisions. Int J Radiat Oncol Biol Phys 2017;98:733-740.
    Int J Radiat Oncol Biol Phys. 2018;100:532.
    PubMed     Text format    


    J Clin Oncol

  46. TRAINA TA, Miller K, Yardley DA, Eakle J, et al
    Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
    J Clin Oncol. 2018 Jan 26:JCO2016713495. doi: 10.1200/JCO.2016.71.3495.
    PubMed     Text format     Abstract available

  47. LAENKHOLM AV, Jensen MB, Eriksen JO, Rasmussen BB, et al
    PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer.
    J Clin Oncol. 2018 Jan 25:JCO2017746586. doi: 10.1200/JCO.2017.74.6586.
    PubMed     Text format     Abstract available

  48. DIELI-CONWRIGHT CM, Courneya KS, Demark-Wahnefried W, Sami N, et al
    Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial.
    J Clin Oncol. 2018 Jan 22:JCO2017757526. doi: 10.1200/JCO.2017.75.7526.
    PubMed     Text format     Abstract available

  49. PIVOT X, Bondarenko I, Nowecki Z, Dvorkin M, et al
    Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive E
    J Clin Oncol. 2018 Jan 26:JCO2017740126. doi: 10.1200/JCO.2017.74.0126.
    PubMed     Text format     Abstract available

  50. HAWLEY ST, Li Y, An LC, Resnicow K, et al
    Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial.
    J Clin Oncol. 2018 Jan 24:JCO2017748442. doi: 10.1200/JCO.2017.74.8442.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  51. LINDSTROM LS, Yau C, Czene K, Thompson CK, et al
    Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
    J Natl Cancer Inst. 2018 Jan 19. pii: 4780395. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Surg Oncol

  52. GERVAIS MK, Burtenshaw SM, Maxwell J, Dickson BC, et al
    Clinical outcomes in breast angiosarcoma patients: A rare tumor with unique challenges.
    J Surg Oncol. 2017;116:1056-1061.
    PubMed     Text format     Abstract available


    Nat Rev Clin Oncol

  53. VAZ-LUIS I, Partridge AH
    Exogenous reproductive hormone use in breast cancer survivors and previvors.
    Nat Rev Clin Oncol. 2018 Jan 23. pii: nrclinonc.2017.
    PubMed     Text format     Abstract available


    NPJ Breast Cancer

  54. YERUVA SLH, Zhao F, Miller KD, Tevaarwerk AJ, et al
    E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer.
    NPJ Breast Cancer. 2018;4:1.
    PubMed     Text format     Abstract available


    Oncogene

  55. ZHANG Y, Wester L, He J, Geiger T, et al
    IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer.
    Oncogene. 2018 Jan 22. pii: 10.1038/s41388-017-0027.
    PubMed     Text format     Abstract available

  56. LIAO Y, Xia X, Liu N, Cai J, et al
    Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination.
    Oncogene. 2018 Jan 22. pii: 10.1038/s41388-017-0069.
    PubMed     Text format     Abstract available

  57. LIANG H, Xiao J, Zhou Z, Wu J, et al
    Hypoxia induces miR-153 through the IRE1alpha-XBP1 pathway to fine tune the HIF1alpha/VEGFA axis in breast cancer angiogenesis.
    Oncogene. 2018 Jan 25. pii: 10.1038/s41388-017-0089.
    PubMed     Text format     Abstract available

  58. BROWNE AL, Charmsaz S, Vareslija D, Fagan A, et al
    Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer.
    Oncogene. 2018 Jan 25. pii: 10.1038/s41388-017-0042.
    PubMed     Text format     Abstract available

  59. IRELAND L, Santos A, Campbell F, Figueiredo C, et al
    Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer.
    Oncogene. 2018 Jan 25. pii: 10.1038/s41388-017-0115.
    PubMed     Text format     Abstract available


    PLoS One

  60. SYED BM, Morgan D, Setty T, Green AR, et al
    Correction: Oestrogen receptor negative early operable primary breast cancer in older women-Biological characteristics and long-term clinical outcome.
    PLoS One. 2018;13:e0191979.
    PubMed     Text format     Abstract available

  61. KIM J, Choi SH, Ham SJ, Cho YC, et al
    Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model.
    PLoS One. 2018;13:e0187063.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  62. SAMANTA D, Park Y, Ni X, Li H, et al
    Chemotherapy induces enrichment of CD47(+)/CD73(+)/PDL1(+) immune evasive triple-negative breast cancer cells.
    Proc Natl Acad Sci U S A. 2018 Jan 24. pii: 1718197115.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: